Company: IOBT
Filing Date: 2025-03-04
Form Type: 8-K
Source: 0001193125-25-045673
Chunk: 0

Company: IO Biotech, Inc.
Filing Date: 2025-03-04
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02      Results of Operations and Financial Condition.  

As discussed below, IO Biotech, Inc., a Delaware corporation (the “ Company”), issued a press release on March 4, 2025. In its press release, the Company disclosed a cash and cash equivalents balance of approximately $60 million as of December 31, 2024.

Because the Company’s consolidated financial statements for the year ended December 31, 2024 have not yet been finalized or audited, the preliminary statement of the Company’s cash and cash equivalents as of December 31, 2024 in this Item 2.02 is subject to change, and the Company’s actual cash and cash equivalents as of December 31, 2024 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.